CDK2-IN-47

• Description:

  CDK2-IN-47 is a potent CDK2 inhibitor with an IC50 of 0.21 μM. CDK2-IN-47 exhibits outstanding anticancer activity against MCF-7, HCT-116, and MGC-803 cell lines. CDK2-IN-47 effectively induces G1 cell cycle arrest, retinoblastoma protein (Rb) dephosphorylation, and significant apoptosis. CDK2-IN-47 can be used for the studies of breast cancer, colorectal cancer and gastric cancer[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; CDK

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Smiles:

  O=C1C (C) =CN (CC (N[C@H] (CC (C) C) C (OC) =O) =O) C2=NC (SC) =NN12

• Molecular Formula:

  C16H23N5O4S

• Molecular Weight:

  381.45

• References & Citations:

  [1]Nagy IM, et al. Design, synthesis, biological and computational evaluation of novel S/N-glycerolyl and peptide-conjugated [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent CDK2 inhibitors for anticancer therapy. Bioorg Chem. 2025 Sep 2;165:108952.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK1; CDK2; CDK4; CDK6; CDK7; CDK9